Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/41756
Title: | Effects of Recombinant IL-13 Treatment on Gut Microbiota Composition and Functional Recovery after Hemisection Spinal Cord Injury in Mice | Authors: | HAMAD, Ibrahim VAN BROECKHOVEN, Jana CARDILLI, Alessio HELLINGS, Niels Strowig, Till LEMMENS, Stefanie HENDRIX, Sven KLEINEWIETFELD, Markus |
Issue Date: | 2023 | Publisher: | MDPI | Source: | Nutrients, 15 (19) (Art N° 4184) | Abstract: | In recent years, the gut-central nervous system axis has emerged as a key factor in the pathophysiology of spinal cord injury (SCI). Interleukin-13 (IL-13) has been shown to have anti-inflammatory and neuroprotective effects in SCI. The aim of this study was to investigate the changes in microbiota composition after hemisection injury and to determine whether systemic recombinant (r)IL-13 treatment could alter the gut microbiome, indirectly promoting functional recovery. The gut microbiota composition was determined by 16S rRNA gene sequencing, and correlations between gut microbiota alterations and functional recovery were assessed. Our results showed that there were no changes in alpha diversity between the groups before and after SCI, while PERMANOVA analysis for beta diversity showed significant differences in fecal microbial communities. Phylogenetic classification of bacterial families revealed a lower abundance of the Bacteroidales S24-7 group and a higher abundance of Lachnospiraceae and Lactobacillaceae in the post-SCI group. Systemic rIL-13 treatment improved functional recovery 28 days post-injury and microbiota analysis revealed increased relative abundance of Clostridiales vadin BB60 and Acetitomaculum and decreased Anaeroplasma, Ruminiclostridium_6, and Ruminococcus compared to controls. Functional assessment with PICRUSt showed that genes related to glyoxylate cycle and palmitoleate biosynthesis-I were the predominant signatures in the rIL-13-treated group, whereas sulfolactate degradation super pathway and formaldehyde assimilation-I were enriched in controls. In conclusion, our results indicate that rIL-13 treatment promotes changes in gut microbial communities and may thereby contribute indirectly to the improvement of functional recovery in mice, possibly having important implications for the development of novel treatment options for SCI. | Notes: | Kleinewietfeld, M (corresponding author), Hasselt Univ, Ctr Inflammat Res IRC, VIB Lab Translat Immunomodulat, B-3590 Diepenbeek, Belgium.; Kleinewietfeld, M (corresponding author), Hasselt Univ, Biomed Res Inst BIOMED, Dept Immunol & Infect, B-3590 Diepenbeek, Belgium.; Hendrix, S (corresponding author), Med Sch Hamburg, Inst Translat Med, D-20457 Hamburg, Germany. ana.vanbroeckhoven@uhasselt.be; alessio.cardilli@uhasselt.be; niels.hellings@uhasselt.be; sven.hendrix@medicalschool-hamburg.de; markus.kleinewietfeld@uhasselt.be |
Keywords: | spinal cord injury;inflammation;microbiome;dysbiosis;interleukin-13;regeneration | Document URI: | http://hdl.handle.net/1942/41756 | e-ISSN: | 2072-6643 | DOI: | 10.3390/nu15194184 | ISI #: | 001083825900001 | Rights: | 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Effects of Recombinant IL-13 Treatment on Gut Microbiota Composition and Functional Recovery after Hemisection Spinal Cord Injury in Mice.pdf | Published version | 3.26 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.